Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study

Ebina, Kosuke; Hashimoto, Motomu; Yamamoto, Wataru; Hirano, Toru; Hara, Ryota; Katayama, Masaki; Onishi, Akira; Nagai, Koji; Son, Yonsu; Amuro, Hideki; Yamamoto, Keiichi; Maeda, Yuichi; Murata, Koichi; Jinno, Sadao; Takeuchi, Tohru; Hirao, Makoto; Kumanogoh, Atsushi; Yoshikawa, Hideki

doi:https://doi.org/10.1186/s13075-019-1880-4

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study

Ebina, Kosuke; Hashimoto, Motomu; Yamamoto, Wataru et al.

Arthritis Research and Therapy, 2019, 21(1), 91

アクセス数:139件（2025-04-06 21:11 集計）

固定URL: https://hdl.handle.net/11094/93210

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ArthritisResTher_21_1	pdf	なし	1.33 MB	64	2023.11.28

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000060512845 1000060512845 著者名 Hashimoto, Motomu
	著者名 Yamamoto, Wataru
	著者名 Hirano, Toru
	NRID 1000010597107 1000010597107 著者名 Hara, Ryota
	著者名 Katayama, Masaki
	NRID 1000060634269 1000060634269 著者名 Onishi, Akira
	NRID 1000030572458 1000030572458 著者名 Nagai, Koji
	著者名 Son, Yonsu
	著者名 Amuro, Hideki
	著者名 Yamamoto, Keiichi
	NRID 1000010815658 1000010815658 Scopus Author ID 56655338200 56655338200 著者名 Maeda, Yuichi
	NRID 1000060806793 1000060806793 著者名 Murata, Koichi
	著者名 Jinno, Sadao
	NRID 1000010330078 1000010330078 著者名 Takeuchi, Tohru
	NRID 1000010527708 1000010527708 Scopus Author ID 8883255100 8883255100 著者名 Hirao, Makoto
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 著者名 Kumanogoh, Atsushi
	NRID 1000060191558 1000060191558 著者名 Yoshikawa, Hideki
キーワード等	ANSWER cohort
	Biological disease-modifying antirheumatic drugs
	Discontinuation
	Rheumatoid arthritis
内容	Ebina K., Hashimoto M., Yamamoto W., et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study. Arthritis Research and Therapy 21, 91 (2019); https://doi.org/10.1186/s13075-019-1880-4.
抄録	Background: The aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). Methods: This multi-center, retrospective study assessed 4466 treatment courses of 2494 patients with bDMARDs from 2009 to 2017 (females, 82.4%; baseline age, 57.4 years; disease duration 8.5 years; rheumatoid factor positivity 78.6%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone (PSL) 2.7 mg/day (43.1%) and methotrexate (MTX) 5.0 mg/week (61.8%); and 63.6% patients were bio-naïve). Treatment courses included tocilizumab (TCZ; n = 895), etanercept (ETN; n = 891), infliximab (IFX; n = 748), abatacept (ABT; n = 681), adalimumab (ADA; n = 558), golimumab (GLM; n = 464), and certolizumab pegol (CZP; n = 229). Drug retention rates and discontinuation reasons were estimated at 36 months using the Kaplan-Meier method and adjusted for potential confounders (age, sex, disease duration, concomitant PSL and MTX, and switched number of bDMARDs) using Cox proportional hazards modeling. Results: A total of 56.9% of treatment courses were stopped, with 25.8% stopping due to lack of effectiveness, 12.7% due to non-toxic reasons, 11.9% due to toxic adverse events, and 6.4% due to disease remission. Drug retention rates for each discontinuation reason were as follows: lack of effectiveness [from 65.5% (IFX) to 81.7% (TCZ); with significant differences between groups (Cox P < 0.001)], toxic adverse events [from 81.8% (IFX) to 94.0% (ABT), Cox P < 0.001], and remission [from 92.4% (ADA and IFX) to 97.7% (ETN), Cox P < 0.001]. Finally, overall retention rates excluding non-toxic reasons and remission for discontinuation ranged from 53.4% (IFX) to 75.5% (ABT) (Cox P < 0.001). Conclusions: TCZ showed the lowest discontinuation rate by lack of effectiveness, ABT showed the lowest discontinuation rate by toxic adverse events, ADA and IFX showed the highest discontinuation rate by remission, and ABT showed the highest overall retention rates (excluding non-toxic reasons and remission) among seven bDMARDs in the adjusted model.
出版者	BioMed Central Ltd
収録物名	Arthritis Research and Therapy
巻(号)	21(1)
ページ	91
刊行年月	2019-12-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93210
PISSN	14786354
eISSN	14786362
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1186/s13075-019-1880-4
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Arthritis Research and Therapy. 2019, 21(1), p. 91
DC.title	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study
DC.creator	Ebina, Kosuke
	Hashimoto, Motomu
	Yamamoto, Wataru
	Hirano, Toru
	Hara, Ryota
	Katayama, Masaki
	Onishi, Akira
	Nagai, Koji
	Son, Yonsu
	Amuro, Hideki
	Yamamoto, Keiichi
	Maeda, Yuichi
	Murata, Koichi
	Jinno, Sadao
	Takeuchi, Tohru
	Hirao, Makoto
	Kumanogoh, Atsushi
	Yoshikawa, Hideki
DC.publisher	BioMed Central Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2019-12-01
DC.identifier	https://doi.org/10.1186/s13075-019-1880-4
DC.subject	ANSWER cohort
	Biological disease-modifying antirheumatic drugs
	Discontinuation
	Rheumatoid arthritis
DC.description	Ebina K., Hashimoto M., Yamamoto W., et al. Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study. Arthritis Research and Therapy 21, 91 (2019); https://doi.org/10.1186/s13075-019-1880-4.
DCTERMS.abstract	Background: The aim of this study is to evaluate the retention rates and reasons for discontinuation for seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). Methods: This multi-center, retrospective study assessed 4466 treatment courses of 2494 patients with bDMARDs from 2009 to 2017 (females, 82.4%; baseline age, 57.4 years; disease duration 8.5 years; rheumatoid factor positivity 78.6%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate, 4.3; concomitant prednisolone (PSL) 2.7 mg/day (43.1%) and methotrexate (MTX) 5.0 mg/week (61.8%); and 63.6% patients were bio-naïve). Treatment courses included tocilizumab (TCZ; n = 895), etanercept (ETN; n = 891), infliximab (IFX; n = 748), abatacept (ABT; n = 681), adalimumab (ADA; n = 558), golimumab (GLM; n = 464), and certolizumab pegol (CZP; n = 229). Drug retention rates and discontinuation reasons were estimated at 36 months using the Kaplan-Meier method and adjusted for potential confounders (age, sex, disease duration, concomitant PSL and MTX, and switched number of bDMARDs) using Cox proportional hazards modeling. Results: A total of 56.9% of treatment courses were stopped, with 25.8% stopping due to lack of effectiveness, 12.7% due to non-toxic reasons, 11.9% due to toxic adverse events, and 6.4% due to disease remission. Drug retention rates for each discontinuation reason were as follows: lack of effectiveness [from 65.5% (IFX) to 81.7% (TCZ); with significant differences between groups (Cox P < 0.001)], toxic adverse events [from 81.8% (IFX) to 94.0% (ABT), Cox P < 0.001], and remission [from 92.4% (ADA and IFX) to 97.7% (ETN), Cox P < 0.001]. Finally, overall retention rates excluding non-toxic reasons and remission for discontinuation ranged from 53.4% (IFX) to 75.5% (ABT) (Cox P < 0.001). Conclusions: TCZ showed the lowest discontinuation rate by lack of effectiveness, ABT showed the lowest discontinuation rate by toxic adverse events, ADA and IFX showed the highest discontinuation rate by remission, and ABT showed the highest overall retention rates (excluding non-toxic reasons and remission) among seven bDMARDs in the adjusted model.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93210
citation_title	Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study
citation_author	Ebina, Kosuke
	Hashimoto, Motomu
	Yamamoto, Wataru
	Hirano, Toru
	Hara, Ryota
	Katayama, Masaki
	Onishi, Akira
	Nagai, Koji
	Son, Yonsu
	Amuro, Hideki
	Yamamoto, Keiichi
	Maeda, Yuichi
	Murata, Koichi
	Jinno, Sadao
	Takeuchi, Tohru
	Hirao, Makoto
	Kumanogoh, Atsushi
	Yoshikawa, Hideki
citation_publisher	BioMed Central Ltd
citation_language	英語
citation_date	2019-12-01
citation_journal_title	Arthritis Research and Therapy
citation_volume	21
citation_issue	1
citation_firstpage	91
citation_doi	https://doi.org/10.1186/s13075-019-1880-4
citation_public_url	https://hdl.handle.net/11094/93210

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis - The ANSWER cohort study

閲覧可能ファイル

論文情報

論文詳細を表示